NEW YORK (GenomeWeb News) – Personal Genome Diagnostics today announced a deal with MolecularMD to market personalized medicine services to oncology researchers and drug developers.
The deal combines PGDx's expertise in next-generation sequencing-based cancer biomarker discovery with MolecularMD's capabilities in developing and validating cancer companion diagnostics, PGDx said. Under the agreement's terms, the two companies will co-market each other's services to drug manufacturers and biotechnology customers.
Further financial terms were not disclosed.
Baltimore-based PGDx provides genome mapping services and analyses to cancer researchers, clinicians, and patients. In the spring it announced a collaboration with BluePrint Medicines aimed at novel kinase targets for cancer drugs. The company licenses digital karyotyping technology from Johns Hopkins University that was developed by PGDx's founders.
MolecularMD, headquartered in Portland, Ore., provides molecular diagnostic products and services to the pharmaceutical and biotechnology sector.
"This collaboration will now enable the two companies to provide a complete spectrum of genomic services to drug developers," Antony Newton, chief commercial officer of PGDx, said in a statement.